Open AccessIntravitreal ranibizumab for choroidal neovascularization in a patient with angioid streaks and multiple evanescent white dots
Author(s) -
Alfredo Pece,
Davide Allegrini,
Stelios Dimitrios Kontadakis,
Giuseppe Querques,
Luca Rossetti
Publication year - 2016
Publication title -
bmc ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.877
H-Index - 43
ISSN - 1471-2415
DOI - 10.1186/s12886-016-0307-0
Subject(s) - medicine , angioid streaks , choroidal neovascularization , ranibizumab , ophthalmology , visual acuity , fluorescein angiography , bevacizumab , surgery , chemotherapy
Background To report a patient with angioid streaks (ASs) and coincident multiple evanescent white dot syndrome (MEWDS) who developed choroidal neovascularization (CNV). Case presentation A 20-year-old woman presented with reduced vision (20/100) in her left eye (LE). Based on a complete ophthalmologic examination the patient was diagnosed with ASs and coincident MEWDS. Two weeks later best-corrected visual acuity (BCVA) improved up to 20/25 and the MEWDS findings almost disappeared. Two months later BCVA dropped again (20/100) due to the development of CNV which was treated by a single intravitreal injection of ranibizumab (0.5 mg/0.05 mL). One month after this BCVA improved up to 20/40, and there was regression of the CNV. There was no need for retreatment at the last follow-up visit, 1 year after the ranibizumab injection, when the patient showed further recovery of BCVA up to 20/25. Conclusions In this case of ASs, MEWDS completely resolved after 2 weeks, but 2 months later CNV developed. A single intravitreal injection of ranibizumab had a long-lasting effect. Larger series are necessary to clarify the pathogenesis of CNV in such cases and the role of intravitreal ranibizumab.